NCT07107750 2026-02-04
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Not yet recruiting
Clinical Trials
12 trialsNCT06546969 2025-12-10
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
Phase 1 Recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT01679405 2019-09-06
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
Phase 1 Terminated
NCT01297998 2017-11-17
A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
Kansai Hepatobiliary Oncology Group
Phase 1 Completed
NCT01713387 2017-10-09
A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
Kansai Hepatobiliary Oncology Group
Phase 1 Completed
NCT01242605 2016-05-13
ABC-04
University College, London
Phase 1 Completed
NCT01949870 2016-05-13
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
AstraZeneca
Phase 1 Terminated
NCT01291615 2014-10-23
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
Kansai Hepatobiliary Oncology Group
Phase 1 Completed
NCT00551096 2013-12-25
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
University of Colorado, Denver
Phase 1 Completed
NCT00626158 2012-04-04
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
University of California, San Francisco
Phase 1 Completed